113 related articles for article (PubMed ID: 31733287)
21. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas.
Doucette T; Rao G; Rao A; Shen L; Aldape K; Wei J; Dziurzynski K; Gilbert M; Heimberger AB
Cancer Immunol Res; 2013 Aug; 1(2):112-22. PubMed ID: 24409449
[TBL] [Abstract][Full Text] [Related]
22. Angiogenin Upregulation Independently Predicts Unfavorable Overall Survival in Proneural Subtype of Glioblastoma.
Hu JL; Luo WJ; Wang H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819846636. PubMed ID: 31072237
[TBL] [Abstract][Full Text] [Related]
23. Molecular subtypes of glioma identified by genome-wide methylation profiling.
Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ
Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961
[TBL] [Abstract][Full Text] [Related]
24. Cancer Subtype Discovery Using Prognosis-Enhanced Neural Network Classifier in Multigenomic Data.
Vasudevan P; Murugesan T
Technol Cancer Res Treat; 2018 Jan; 17():1533033818790509. PubMed ID: 30092720
[TBL] [Abstract][Full Text] [Related]
25. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
[TBL] [Abstract][Full Text] [Related]
26. Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution.
Li R; Li H; Yan W; Yang P; Bao Z; Zhang C; Jiang T; You Y
Oncotarget; 2015 Mar; 6(9):7318-24. PubMed ID: 25821160
[TBL] [Abstract][Full Text] [Related]
27. Simulating PDGF-Driven Glioma Growth and Invasion in an Anatomically Accurate Brain Domain.
Massey SC; Rockne RC; Hawkins-Daarud A; Gallaher J; Anderson ARA; Canoll P; Swanson KR
Bull Math Biol; 2018 May; 80(5):1292-1309. PubMed ID: 28842831
[TBL] [Abstract][Full Text] [Related]
28. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.
Zheng H; Ying H; Yan H; Kimmelman AC; Hiller DJ; Chen AJ; Perry SR; Tonon G; Chu GC; Ding Z; Stommel JM; Dunn KL; Wiedemeyer R; You MJ; Brennan C; Wang YA; Ligon KL; Wong WH; Chin L; DePinho RA
Nature; 2008 Oct; 455(7216):1129-33. PubMed ID: 18948956
[TBL] [Abstract][Full Text] [Related]
29. Molecular and Genomic Alterations in Glioblastoma Multiforme.
Crespo I; Vital AL; Gonzalez-Tablas M; Patino Mdel C; Otero A; Lopes MC; de Oliveira C; Domingues P; Orfao A; Tabernero MD
Am J Pathol; 2015 Jul; 185(7):1820-33. PubMed ID: 25976245
[TBL] [Abstract][Full Text] [Related]
30. The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres.
Gilder AS; Natali L; Van Dyk DM; Zalfa C; Banki MA; Pizzo DP; Wang H; Klemke RL; Mantuano E; Gonias SL
Sci Rep; 2018 Feb; 8(1):2982. PubMed ID: 29445239
[TBL] [Abstract][Full Text] [Related]
31. Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype.
Wu Y; Fletcher M; Gu Z; Wang Q; Costa B; Bertoni A; Man KH; Schlotter M; Felsberg J; Mangei J; Barbus M; Gaupel AC; Wang W; Weiss T; Eils R; Weller M; Liu H; Reifenberger G; Korshunov A; Angel P; Lichter P; Herrmann C; Radlwimmer B
Nat Commun; 2020 Dec; 11(1):6434. PubMed ID: 33339831
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
[TBL] [Abstract][Full Text] [Related]
33. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
34. Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression.
Murata H; Yoshimoto K; Hatae R; Akagi Y; Mizoguchi M; Hata N; Kuga D; Nakamizo A; Amano T; Sayama T; Iihara K
J Neurooncol; 2015 Oct; 125(1):33-41. PubMed ID: 26272600
[TBL] [Abstract][Full Text] [Related]
35. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.
Park AK; Kim P; Ballester LY; Esquenazi Y; Zhao Z
Neuro Oncol; 2019 Jan; 21(1):59-70. PubMed ID: 30053126
[TBL] [Abstract][Full Text] [Related]
36. Molecular Subgroups of Glioblastoma- an Assessment by Immunohistochemical Markers.
Nagy Á; Garzuly F; Padányi G; Szűcs I; Feldmann Á; Murnyák B; Hortobágyi T; Kálmán B
Pathol Oncol Res; 2019 Jan; 25(1):21-31. PubMed ID: 28948518
[TBL] [Abstract][Full Text] [Related]
37. Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining.
Faried A; Hermanto Y; Tjahjono FP; Valentino A; Arifin MZ
World Neurosurg; 2020 Mar; 135():e137-e163. PubMed ID: 31785437
[TBL] [Abstract][Full Text] [Related]
38. Histologically defined intratumoral sequencing uncovers evolutionary cues into conserved molecular events driving gliomagenesis.
Prabhu A; Kesarwani P; Kant S; Graham SF; Chinnaiyan P
Neuro Oncol; 2017 Nov; 19(12):1599-1606. PubMed ID: 28541485
[TBL] [Abstract][Full Text] [Related]
39. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
Eskilsson E; Rosland GV; Talasila KM; Knappskog S; Keunen O; Sottoriva A; Foerster S; Solecki G; Taxt T; Jirik R; Fritah S; Harter PN; Välk K; Al Hossain J; Joseph JV; Jahedi R; Saed HS; Piccirillo SG; Spiteri I; Leiss L; Euskirchen P; Graziani G; Daubon T; Lund-Johansen M; Enger PØ; Winkler F; Ritter CA; Niclou SP; Watts C; Bjerkvig R; Miletic H
Neuro Oncol; 2016 Dec; 18(12):1644-1655. PubMed ID: 27286795
[TBL] [Abstract][Full Text] [Related]
40. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.
Teng J; da Hora CC; Kantar RS; Nakano I; Wakimoto H; Batchelor TT; Chiocca EA; Badr CE; Tannous BA
Neuro Oncol; 2017 Jun; 19(6):820-832. PubMed ID: 28062830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
